North China Pharmaceutical: Subsidiary Obtains Approval Notice for Clinical Trial of Recombinant Tetanus Vaccine

North China Pharmaceutical announced that its subsidiary, North China Pharmaceutical Jintan Biotechnology Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the recombination tetanus vaccine, approving the company to conduct clinical trials for tetanus prevention.